four
serotyp
flaviviru
dengu
viru
caus
common
mosquitoborn
viral
diseas
human
worldwid
million
peopl
infect
annual
billion
peopl
risk
denv
infect
asymptomat
caus
spectrum
diseas
rang
classic
dengu
fever
df
sever
lifethreaten
form
term
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
approxim
dengu
patient
requir
hospit
annual
larg
proport
children
although
sever
antivir
vaccin
candid
variou
phase
preclin
clinic
evalu
current
treatment
remain
support
care
immun
respons
primari
denv
infect
character
earli
igm
respons
follow
igg
respons
predominantli
subclass
b
cell
stimul
develop
denvspecif
b
cell
either
differenti
memori
b
cell
mbc
resid
secondari
lymphoid
organ
plasma
cell
pc
secret
antigenspecif
antibodi
ab
shortliv
pc
activ
acut
infect
longliv
pc
llpc
migrat
bone
marrow
respons
longterm
humor
immun
mbc
retain
antigenspecif
ab
surfac
llpc
secret
antigenspecif
ab
undergo
affin
matur
clone
bear
ab
highest
affin
surviv
longterm
process
take
sever
week
acut
infect
continu
despit
absenc
circul
antigen
secondari
denv
infect
mbc
rapidli
activ
prior
denv
infect
provid
robust
immun
homotyp
denv
serotyp
contrast
heterotyp
infect
associ
higher
incid
dhfdss
possibl
attribut
part
antibodydepend
enhanc
ade
preform
ab
infect
serotyp
bind
neutral
infect
serotyp
instead
facilit
increas
viral
uptak
bear
cell
addit
ade
crossreact
cell
form
denv
infect
overactiv
potenti
contribut
dengu
pathogenesi
howev
vast
major
denv
infect
asymptomat
result
mild
diseas
suggest
protect
immun
respons
denv
neutral
requir
suffici
level
neutral
ab
number
ab
bound
singl
virion
exceed
threshold
enhanc
depend
antibodi
avid
access
epitop
viru
particl
avid
antiflaviviru
monoclon
ab
mab
shown
posit
correl
neutral
activ
vitro
consist
lower
neutral
activ
observ
mab
lower
affin
variant
genotyp
within
singl
denv
serotyp
howev
relat
neutral
activ
polyclon
serum
avid
still
unclear
measur
igg
avid
shown
discrimin
denv
infect
polyclon
serum
follow
longitudin
studi
analyz
denvspecif
neutral
capac
igm
igg
avid
denv
serum
sampl
hospitalbas
studi
managua
nicaragua
nicaragua
one
denv
serotyp
tend
domin
sever
year
denv
serotyp
cocircul
lower
level
domin
serotyp
prior
predomin
serotyp
predomin
circul
low
level
nicaragua
studi
denv
infect
acut
phase
month
postinfect
infect
measur
neutral
ab
titer
avid
current
infect
serotyp
preval
previous
circul
serotyp
prototyp
assess
crossreact
respons
crossprotect
ab
concentr
avid
play
signific
role
viru
neutral
test
possibl
correl
igm
igg
avid
denv
total
ab
titer
denvspecif
neutral
titer
protocol
studi
review
approv
institut
review
board
irb
univers
california
berkeley
nicaraguan
ministri
health
parent
legal
guardian
subject
provid
written
inform
consent
subject
year
age
older
provid
assent
design
execut
studi
inclus
criteria
studi
popul
laboratori
test
confirm
denv
infect
patient
previous
describ
briefli
studi
enrol
occur
nicaraguan
nation
pediatr
refer
hospit
hospit
infantil
manuel
de
rivera
himjr
managua
august
januari
peak
dengu
season
inclus
criteria
includ
age
year
age
sampl
collect
consecut
day
enrol
acut
day
onset
symptom
convalesc
postil
denv
infect
confirm
revers
chain
reaction
rtpcr
amplif
viral
rna
isol
denv
aed
albopictu
cell
seroconvers
denvspecif
igm
ab
measur
igm
captur
enzymelink
immunosorb
assay
elisa
acutephas
convalescentphas
serum
sampl
andor
increas
total
ab
titer
measur
inhibit
elisa
pair
acut
convalescentphas
serum
sampl
previous
describ
denv
infect
defin
ab
titer
inhibit
elisa
acutephas
sampl
respect
andor
convalesc
phase
sampl
respect
total
ab
titer
measur
acut
convalesc
phase
infect
decreas
substanti
thereaft
denv
propag
aed
albopictu
cell
previous
describ
cell
supernat
concentr
centrifug
amicon
filter
kda
min
ultracentrifug
h
beckman
resuspend
pb
strain
passag
strain
passag
clinic
strain
nicaraguan
patient
isol
nation
virolog
laboratori
managua
passag
minim
rajidcsignr
cell
gift
b
doranz
integr
molecular
philadelphia
pa
grown
medium
invitrogen
fb
use
neutral
assay
serum
sampl
heatinactiv
min
dilut
fb
ph
use
eight
dilut
neutral
assess
flow
cytometri
use
gfpexpress
denv
report
viru
particl
rvp
previous
describ
percent
infect
serum
dilut
calcul
relat
noserum
control
data
express
percent
infect
versu
reciproc
serum
dilut
fit
sigmoid
doserespons
curv
use
graphpad
prism
softwar
la
jolla
ca
determin
titer
ab
achiev
reduct
infect
neutral
titer
express
reciproc
serum
dilut
serum
avid
measur
use
modifi
elisa
protocol
urea
wash
use
dilut
pfuml
yield
od
use
polyval
serum
standard
amount
amount
use
pandenv
mab
gift
g
screaton
imperi
colleg
uk
serial
dilut
dilut
coat
incub
mab
dilut
pfuml
yield
od
use
thereaft
determin
serum
igg
avid
plate
coat
whole
viru
incub
heatinactiv
dilut
serum
sampl
triplic
wash
urea
pb
min
ad
secondari
biotinconjug
ab
donkey
antihuman
igg
streptavidinap
conjug
pnpp
substrat
use
sampl
studi
popul
previous
optim
amount
urea
use
urea
denv
infect
urea
denv
infect
yield
best
result
analyz
serum
avid
denv
time
measur
serum
igm
avid
donkey
antihuman
igm
fcfragmentspecif
mab
jackson
immunoresearch
use
secondari
ab
acutephas
sampl
day
postonset
symptom
chosen
background
level
measur
dengueneg
human
sera
sampl
avid
calcul
percentag
igg
igm
bound
divid
backgroundadjust
od
urea
wash
adjust
od
pb
wash
qualiti
control
criteria
includ
background
od
polyval
serum
posit
control
background
od
posit
control
plate
within
mean
sd
control
plate
control
plate
coat
either
incub
polyval
serum
half
plate
wash
urea
second
half
wash
pb
mean
sd
polyval
posit
control
calcul
urea
concentr
viru
follow
data
stratifi
infect
statu
analysi
gender
evalu
possibl
modifi
geometr
mean
total
ab
titer
percentag
avid
compar
use
twosid
wilcoxon
sign
rank
test
detect
differ
follow
timepoint
acut
convalesc
convalesc
geometr
mean
ab
titer
avid
also
compar
infect
statu
timepoint
use
wilcoxon
sign
rank
test
bivari
correl
ab
titer
avid
estim
use
spearman
correl
coeffici
timepoint
test
differ
avid
ab
titer
clinic
sign
dengu
sever
vascular
leak
hypotens
shock
compens
shock
cutan
bleed
hemoconcentr
mucos
bleed
twosid
wilcoxon
sign
rank
test
use
compar
geometr
mean
total
ab
titer
avid
timepoint
stratifi
immun
statu
alpha
p
use
statist
signific
test
calcul
perform
sa
version
sa
institut
cari
nc
august
januari
patient
enrol
suspect
dengu
nation
pediatr
refer
hospit
hijmr
twelv
patient
exclud
analysi
one
patient
drop
studi
enrol
patient
undetermin
dengu
diagnost
result
patient
follow
patient
laboratoryconfirm
rtpcr
andor
viru
isol
includ
analysi
tabl
denv
infect
tabl
note
diseas
sever
rel
low
season
dhfdss
case
tabl
absenc
preinfect
sampl
exclud
previou
infect
hypothes
children
denv
infect
previous
infect
predomin
serotyp
circul
previou
year
thu
use
repres
previous
infect
serotyp
analysi
measur
denvspecif
neutral
capac
patient
sera
infect
current
infect
serotyp
repres
previous
infect
serotyp
infect
use
flow
cytometrybas
assay
determin
acut
convalesc
timepoint
tabl
peak
convalesc
case
significantli
higher
titer
detect
case
figur
infect
observ
signific
increas
acut
convalesc
phase
p
follow
signific
drop
convalesc
postonset
symptom
p
decreas
p
figur
infect
note
similar
pattern
p
pair
adjac
timepoint
figur
addit
infect
measur
neutral
capac
serum
show
similar
trend
figur
measur
denvspecif
igg
serum
avid
denvspecif
igm
serum
avid
use
modifi
elisa
urea
wash
avid
defin
percentag
igg
igm
remain
bound
urea
wash
infect
observ
larg
increas
igg
serum
avid
convalesc
postonset
symptom
p
rise
month
p
month
p
postonset
symptom
figur
tabl
igm
serum
avid
acut
sampl
reveal
mean
igm
bound
denv
infect
observ
signific
increas
igg
serum
avid
acut
convalesc
phase
p
rise
later
timepoint
figur
tabl
measur
avid
infect
like
previous
infect
serotyp
observ
significantli
higher
level
igg
bound
acut
phase
p
figur
howev
due
increas
avid
convalesc
phase
signific
differ
avid
detect
two
serotyp
p
figur
subsequ
timepoint
shift
occur
significantli
higher
avid
current
infect
serotyp
p
p
p
respect
figur
note
igg
serum
avid
remain
high
denv
case
declin
case
convalesc
timepoint
figur
abil
serum
neutral
viru
depend
ab
concentr
andor
serum
avid
among
paramet
denv
infect
posit
correl
igm
serum
avid
acut
phase
observ
figur
suggest
contribut
denvspecif
igm
ab
earli
viru
neutral
also
observ
posit
correl
igg
serum
avid
acut
phase
case
timepoint
figur
tabl
due
slow
kinet
affin
matur
highli
avid
igg
like
secret
preexist
mbc
suggest
contribut
denv
crossreact
ab
viru
neutral
moreov
correl
observ
denvspecif
total
ab
titer
acut
phase
infect
tabl
interestingli
posit
correl
note
igg
bound
acut
phase
postinfect
figur
tabl
lastli
posit
correl
observ
igg
serum
avid
acut
convalesc
timepoint
figur
tabl
total
ab
titer
igg
bound
compar
patient
without
follow
clinic
sign
stratifi
immun
statu
compens
shock
hypotens
shock
vascular
leak
cutan
bleed
mucos
bleed
hemoconcentr
defin
differ
observ
mean
total
ab
titer
igg
timepoint
examin
among
infect
use
classif
df
vs
dhfdss
patient
classifi
df
demonstr
statist
signific
differ
mean
igg
bound
compar
classifi
dhfdss
stratifi
immun
statu
except
convalesc
igg
bound
infect
df
dhfdss
p
signific
differ
total
ab
titer
observ
df
dhfdss
case
convalesc
timepoint
p
higher
ab
titer
observ
sever
case
vs
better
understand
protect
immun
respons
natur
denv
infect
critic
develop
safe
effect
vaccin
defin
robust
correl
protect
vaccin
trial
protect
denv
infect
andor
diseas
may
depend
denvspecif
serum
neutral
thu
may
associ
denvspecif
ab
titer
denvspecif
serum
avid
howev
sever
question
remain
unansw
role
igm
ab
whether
serum
avid
correl
serum
neutral
use
longitudin
sampl
seri
hospitalbas
studi
show
first
time
denvspecif
neutral
titer
peak
convalesc
phase
decreas
time
infect
also
observ
increas
avid
convalesc
phase
postinfect
case
acut
convalesc
phase
infect
addit
detect
higher
avid
heterolog
potenti
previous
infect
serotyp
acut
phase
infect
avid
higher
current
infect
serotyp
later
timepoint
final
show
first
time
correl
serum
avid
serum
neutral
titer
context
denv
infect
specif
demonstr
serotypespecif
neutral
titer
correl
serum
igm
avid
acut
denv
infect
serum
igg
avid
denv
infect
studi
show
denvspecif
increas
acut
convalesc
phase
infect
higher
case
wherea
infect
b
cell
stimul
igg
ab
detect
convalesc
phase
crossreact
memori
b
cell
reactiv
case
induc
rapid
increas
denvspecif
igg
ab
serum
neutral
achiev
enough
ab
bind
access
epitop
denv
prevent
bind
target
cell
fusion
viral
endosom
membran
subsequ
releas
viral
rna
cytoplasm
suscept
cell
later
timepoint
decreas
observ
previous
shown
denv
virus
denv
infect
observ
increas
serum
igg
avid
convalesc
phase
reflect
affin
matur
ab
mbc
llpc
develop
b
cell
undergo
affin
matur
select
first
infect
clone
highest
avid
surviv
longterm
lead
higher
mean
igg
avid
time
contrast
denv
infect
observ
increas
serum
igg
avid
earlier
acut
convalesc
phase
explain
affin
matur
newli
activ
b
cell
rather
suggest
crossreact
ab
secret
preexist
mbc
contribut
earli
increas
avid
heterotyp
denv
infect
previou
studi
found
significantli
higher
serum
igg
avid
direct
possibl
previous
infect
denv
serotyp
oppos
current
infect
serotyp
acut
phase
infect
confirm
find
show
subsequ
serum
igg
avid
current
infect
serotyp
increas
time
avid
current
infect
serotyp
greater
previou
infect
serotyp
postinfect
serum
igg
avid
decreas
timepoint
possibl
llpc
displac
bone
marrow
replac
newli
gener
llpc
llpc
nich
limit
bone
marrow
newli
form
llpc
replac
llpc
form
earlier
infect
decreas
serum
igg
avid
timepoint
could
explain
strong
extrafollicular
respons
induc
presenc
preexist
antidenv
ab
infect
inhibit
germin
center
respons
thu
inhibit
strong
longterm
immun
current
infect
serotyp
correl
serum
avid
serum
neutral
report
measl
hiv
cytomegaloviru
infect
analyz
whether
denvspecif
serum
avid
total
ab
titer
correl
denvspecif
neutral
denv
infect
neither
igg
serum
avid
denvspecif
total
ab
titer
correl
rather
correl
igm
serum
avid
acut
phase
infect
show
highli
avid
igm
ab
also
highli
neutral
suggest
igm
ab
play
import
role
denvspecif
serum
neutral
contrast
acut
phase
denv
infect
correl
igg
serum
avid
rapid
kinet
appear
igg
ab
denv
infect
slow
affin
matur
process
highli
avid
igg
ab
like
secret
mbc
form
previou
infect
rather
newlyactiv
b
cell
suggest
crossreact
ab
contribut
neutral
acut
denv
infect
consist
isol
strongli
neutral
crossreact
mab
denv
infect
smith
j
crow
r
de
alwi
de
silva
e
harri
unpublish
data
igg
serum
avid
correl
timepoint
suggest
affin
matur
infect
contribut
strengthen
neutral
activ
serum
ab
also
observ
correl
igg
serum
avid
support
relat
crossreact
ab
neutral
furthermor
posit
correl
denvspecif
total
ab
titer
acut
denv
infect
found
show
greater
amount
ab
correl
neutral
activ
sinc
dengu
diseas
sever
may
associ
subneutr
enhanc
concentr
denvspecif
ab
analyz
titer
igg
serum
avid
among
df
vs
dhfdss
patient
among
case
differ
clinic
sign
sever
find
mani
signific
differ
howev
could
due
rel
low
diseas
sever
epidem
nicaragua
thu
small
sampl
size
dhfdss
final
preinfect
sampl
avail
hospitalbas
studi
thu
chose
one
like
previou
infect
serotyp
analyz
group
patient
analysi
sampl
collect
document
sequenti
infect
longterm
prospect
dengu
cohort
studi
enabl
precis
investig
crossreact
ab
denv
infect
overal
studi
show
igm
crossreact
igg
contribut
neutral
acut
denv
infect
support
result
conduct
addit
analys
denvspecif
serum
neutral
capac
includ
use
chemic
deplet
igm
ab
use
denv
virion
deplet
heterolog
serotyp
crossreact
ab
crossreact
serum
avid
domin
acut
denv
respons
avid
current
infect
serotyp
becom
domin
time
signific
correl
observ
neutral
ab
titer
serum
avid
current
heterotyp
serotyp
futur
studi
address
relat
avid
infect
outcom
symptomat
vs
inappar
diseas
sever
unexpect
result
first
proofofconcept
dengu
live
attenu
vaccin
efficaci
trial
phase
recent
publish
highlight
critic
need
better
understand
immun
respons
natur
denv
infect
vaccin
candid
identifi
robust
correl
protect
believ
measur
denvspecif
serum
avid
integr
evalu
futur
vaccin
trial
appli
broadli
studi
immun
respons
denv
natur
infect
